Receptor Theory And Signal Transduction

Receptor theory is the branch of pharmacology that explains how drugs produce their effects by binding to specific molecules in the body.

12 frameworks, from 1926 to today · Pharmacology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Receptor theory is the branch of pharmacology that explains how drugs produce their effects by binding to specific molecules in the body1. Its central claim—that a drug does not act on tissues in general but on particular molecular "receptive substances"—was once speculative and is now the foundation of most of medicine. Signal transduction is the study of what happens after that binding: how a chemical message at the cell surface is converted into a change inside the cell2. Together they answer the questions a pharmacologist cannot avoid: why does a drug need a certain shape, why does more drug sometimes mean more effect and sometimes not, why do some drugs block others, and why can two drugs that bind the same receptor do different things?

From "Receptive Substances" to Occupancy: 1870s–1920s

Before receptors existed as a concept, physiologists noticed that drugs acted with striking selectivity. In the 1870s, the German physiologist Rudolf Heidenhain and others observed that certain poisons affected only particular tissues. The English physiologist John Newport Langley pushed this further. Studying the action of nicotine and curare on skeletal muscle around 1905, he concluded that muscle cells carry "receptive substances" that combine with the drug, and that curare works by occupying those substances so nicotine cannot. This was a functional argument: the receptor was inferred because the drug's behaviour demanded it, not because anyone had seen one.

The term "receptor" itself is usually credited to Paul Ehrlich, whose early-twentieth-century "side-chain" theory held that drugs and toxins bind to specific chemical groups on cells, much as a key fits a lock. Ehrlich's work on chemotherapy—notably salvarsan for syphilis—made the lock-and-key metaphor famous, though his receptors were largely hypothetical.

The first quantitative theory came from Archibald Hill and, more fully, from Alfred Joseph Clark in the 1920s and 1930s. Clark measured how much acetylcholine or histamine was needed to contract a piece of frog heart or guinea-pig gut, and found that the response rose with drug concentration along a saturating curve—the same shape as a Langmuir adsorption isotherm, which describes molecules binding to a surface. His conclusion was bold: the effect of a drug is proportional to the fraction of receptors it occupies1. This is occupancy theory. It explained why dose–response curves flatten: once every receptor is occupied, adding more drug changes nothing1. Clark's limitation was that some drugs produced a maximal response while occupying only a small fraction of receptors—so occupancy alone could not be the whole story.

Affinity, Efficacy, and the Mathematics of Antagonism: 1940s–1950s

The next generation turned Clark's idea into a rigorous toolkit. In 1948, E. J. Ariëns distinguished affinity (how tightly a drug binds) from intrinsic activity (how strongly binding translates into response). Around the same time, Heinz Otto Schild in London developed the analysis that still bears his name. Schild studied how a competitive antagonist—a drug that binds the same site as the agonist and blocks it—shifts the agonist's dose–response curve to the right without lowering its maximum1. By measuring that shift at several antagonist concentrations, he derived a quantity, the pA₂ (or the related $K_B$), that estimates the antagonist's affinity independently of the tissue. Schild analysis became the standard proof that two drugs compete for one site.

In 1956, Robert Stephenson refined the picture with two-property theory: a drug has affinity and efficacy, where efficacy is a dimensionless number describing its ability to activate the receptor after binding. Crucially, efficacy could be large enough that a drug occupying a tiny fraction of receptors still produced a full response—resolving Clark's puzzle3. This "spare receptor" idea meant the receptor population could be far larger than needed for maximal effect1. These models, built on isolated smooth muscle and heart preparations, gave pharmacology a predictive language: dose–response curves, EC₅₀ (the concentration giving half-maximal effect), and competitive versus non-competitive blockade.

Second Messengers: 1950s–1960s

Occupancy theory said nothing about what happened inside the cell. That gap was filled by the discovery of second messengers—small molecules that carry a signal from the receptor into the cell's interior4. The key figure was Earl Sutherland at Vanderbilt and Case Western. Studying how adrenaline and glucagon raise blood glucose, he found in the late 1950s that the hormone acts on the outside of the liver cell to generate cyclic AMP (cAMP) inside it, and that cAMP then activates the enzymes that release glucose. The hormone was the "first messenger"; cAMP was the second4. Sutherland won the 1971 Nobel Prize for this work245. The concept transformed pharmacology: a receptor was no longer just a switch but the start of a cascade, and drugs could in principle act at any step.

Finding the Molecules: 1970s–1980s

For decades receptors were inferred from behaviour. The turning point was making them tangible. In the early 1970s, several groups used radioactive drugs that bound tightly and specifically—radioactively labelled antagonists such as the beta-blocker propranolol—to label receptors in tissue membranes and measure binding directly. This radioligand binding allowed saturation, competition, and kinetic experiments that confirmed the affinities Schild had inferred. Then came purification: in the late 1970s and early 1980s, the nicotinic acetylcholine receptor from the electric organ of the Torpedo ray was isolated as a protein complex, and the beta-adrenergic receptor was purified in the mid-1980s. Receptors were real molecules with measurable mass and composition.

G Proteins and the Transduction Machinery: 1970s–1980s

Sutherland's cAMP work raised a question: how does a receptor on the membrane activate an enzyme inside it? The answer was the G protein—a guanine-nucleotide-binding protein that shuttles between receptor and effector. Martin Rodbell, studying glucagon's action in the 1970s, found that GTP was required for hormone effects, implying a GTP-binding intermediary2. Alfred Gilman and colleagues then purified and characterised the stimulatory G protein ($Gs$) that couples receptors to the enzyme adenylyl cyclase, which makes cAMP. Rodbell and Gilman shared the 1994 Nobel Prize24. The G-protein transduction model gave a general mechanism: agonist binds receptor $\rightarrow $ receptor activates G protein $\rightarrow $ G protein activates or inhibits an effector enzyme or ion channel $\rightarrow $ second messenger spreads the signal. Different G proteins ($Gs$, $Gi$, $Gq$) coupled different receptors to different effectors, explaining how one hormone could excite one tissue and inhibit another.

Cloning and the Receptor Superfamilies: 1980s–1990s

The next leap was genetic. In the mid-1980s, the genes for the beta-adrenergic receptor and the muscarinic acetylcholine receptor were cloned. Their sequences revealed a striking shared architecture: seven stretches of hydrophobic amino acids that could span the membrane seven times. This seven-transmembrane (7TM) structure, shared with rhodopsin, defined the largest receptor family—the G-protein-coupled receptors (GPCRs). Cloning also revealed other superfamilies: ligand-gated ion channels (like the nicotinic receptor), tyrosine-kinase receptors (like the insulin receptor), and nuclear receptors. Molecular cloning and superfamily classification turned receptor pharmacology into a comparative science: receptors could be grouped by sequence, and new family members found by homology. It also enabled recombinant expression—putting a single receptor type into a cell line—so that drug effects could be studied without the confound of mixed tissue.

Oligomers, Networks, and Bias: 1990s–2000s

Two assumptions came under pressure. First, receptors were thought to act alone. But evidence accumulated that many GPCRs form dimers or oligomers—pairs or larger assemblies—and that these assemblies can have distinct pharmacology, with one subunit influencing the other's binding or signalling. Second, the idea that a receptor activates one pathway gave way to biased agonism (also called functional selectivity): the observation that different drugs binding the same receptor can preferentially activate one downstream pathway over another6. A drug might, for example, favour G-protein signalling over the arrestin pathway that desensitises the receptor6. This was demonstrated in the 2000s and reframed drug design: "agonist" and "antagonist" became too coarse, and pathway-selective signalling became a design goal. The broader picture was of signalling networks—receptors embedded in crosstalk, feedback, and scaffolding, not simple linear chains.

Structure, Kinetics, and Systems: 2000s–Present

Three further developments define the current field. Structure-based receptor pharmacology became possible as X-ray crystallography and, later, cryo-electron microscopy solved the three-dimensional structures of GPCRs—the beta-adrenergic receptor in 2007, and many others since—showing exactly how drugs sit in the binding pocket and how the receptor changes shape on activation. This let chemists design molecules against a known structure rather than by trial.

Kinetic and residence-time models shifted attention from how tightly a drug binds (affinity) to how long it stays bound. A drug with modest affinity but slow dissociation can produce a long-lasting effect, and residence time became a design parameter, especially for drugs where duration matters more than potency.

Systems pharmacology treats the body as a network of interacting components and asks how a drug's effect emerges from the whole system—accounting for feedback, adaptation, and multiple targets—rather than from a single receptor in isolation7. It descends from the recognition that most diseases involve many pathways and most drugs hit more than one target.

Today the field works across all these levels: atomic structures of receptors, kinetic measurements of drug binding, pathway-resolved signalling assays, and computational models of networks. The open questions are substantial—how to predict which biased ligand will be therapeutic rather than harmful, how receptor oligomers behave in real tissues, how to model signalling in a whole organism, and how to design drugs against the many receptors still without structures. What began as an inference from the behaviour of curare and nicotine is now a molecular science that underpins most of modern drug discovery.

References

  1. Receptor theory (introduction, Receptor occupancy model, Competitive inhibition models, Ternary complex model), Wikipedia
  2. Signal transduction (introduction, History), Wikipedia
  3. Intrinsic activity, Wikipedia
  4. Second messenger system, Wikipedia
  5. Cyclic adenosine monophosphate (History), Wikipedia
  6. Functional selectivity, Wikipedia
  7. Systems pharmacology, Wikipedia

The frameworks of Receptor Theory And Signal Transduction

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1926-1960

    Occupancy Theory

    Is a drug's effect proportional to how many receptors it occupies?

    Fly to its tower in Nousfarer

  2. 1947-1980

    Schild equation

    How can an antagonist's affinity be measured from its shift of an agonist curve?

    Fly to its tower in Nousfarer

  3. 1948-1980

    Two-Property Theory (Affinity and Efficacy)

    Why can two drugs binding equally well produce different maximal effects?

    Fly to its tower in Nousfarer

  4. 1957-1985

    Second messenger system

    How does a signal at the cell surface become a change inside the cell?

    Fly to its tower in Nousfarer

  5. 1970-1995

    Radioligand Binding and Receptor Purification

    Can receptors be measured and isolated as real molecules?

    Fly to its tower in Nousfarer

  6. 1971-Present

    G-Protein Transduction Model

    What molecular machinery carries a signal from receptor to effector?

    Fly to its tower in Nousfarer

  7. 1985-Present

    Molecular Cloning and Receptor Superfamily Classification

    How are receptors related to one another by their genes and sequences?

    Fly to its tower in Nousfarer

  8. 1995-Present

    Receptor Oligomerization and Signalling Networks

    Do receptors act alone or as assemblies in signalling networks?

    Fly to its tower in Nousfarer

  9. 2002-Present

    Functional selectivity

    Can drugs binding the same receptor activate different downstream pathways?

    Fly to its tower in Nousfarer

  10. 2004-Present

    Kinetic and Residence-Time Models

    Does how long a drug stays bound determine its effect?

    Fly to its tower in Nousfarer

  11. 2007-Present

    Structure-Based Receptor Pharmacology

    How does receptor three-dimensional structure explain drug binding and action?

    Fly to its tower in Nousfarer

  12. 2008-Present

    Systems Pharmacology

    How do drug effects emerge from whole networks of interacting molecules?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Occupancy TheorySchild equationTwo-Property Theory (Affinity and Eff…Second messenger systemRadioligand Binding and Receptor Puri…G-Protein Transduction ModelMolecular Cloning and Receptor Superf…Receptor Oligomerization and Signalli…Functional selectivityKinetic and Residence-Time ModelsStructure-Based Receptor PharmacologySystems Pharmacology

Beyond the field

Where Receptor Theory And Signal Transduction's ideas came from in other fields, and what they led to there: the strongest 12 of 48 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Receptor Theory And Signal Transduction is a planet in Nousfarer

Its city has a tower for each of these 12 frameworks. Land, walk in, and climb one concept at a time.

Land on Receptor Theory And Signal Transduction

Related fields

Fields its ideas are linked to

More in Pharmacology

See where Receptor Theory And Signal Transduction sits on the Map of Human Knowledge